Ganesh V. Kaundinya is President and CEO of GlycoEra, a leading precision immunology company.  Glycoera’s Platform enables creation of a portfolio of novel biological products that degrade circulating and membrane proteins in a highly selective and targeted fashion.  Removing disease-causing proteins has broad potential therapeutic applications across autoimmune diseases, oncology, neurology, allergy, and infectious diseases.    Prior to GlycoEra, Dr. Kaundinya was founder and COO and CSO of Momenta Pharmaceuticals which was acquired by J&J for $6.5B in 2020.  Under his guidance, Momenta developed a portfolio of complex generics, biosimilars and novel biologic products that included carbohydrates, complex peptides, glycoproteins, antibodies and Fc fusion proteins, for therapeutic indications in cardiovascular, autoimmune diseases and oncology. Prior to that, Dr. Kaundinya held various roles in academia and industry, and was research faculty at MIT.  He is also a strategic advisor to Innospark Ventures, a boston based VC firm focused on investing at the intersection of AI, machine learning and Healthcare.  Dr. Kaundinya holds degree in Chemical Engineering from Indian Institute of Technology, Madras and MS and PhD from MIT.